TY - JOUR
T1 - Investigation of two novel biochemical markers of inflammation, matrix metalloproteinase and cathepsin generated fragments of C-reactive protein, in patients with ankylosing spondylitis
AU - Skjøt-Arkil, Helene
AU - Schett, Georg
AU - Zhang, Chen
AU - Larsen, Dorthe Vang
AU - Wang, Yaguo
AU - Zheng, Qinlong
AU - Larsen, Martin Røssel
AU - Nawrocki, Arkadiusz
AU - Bay-Jensen, Anne-Christine
AU - Henriksen, Kim
AU - Christiansen, Claus Bohn
AU - Alexandersen, Peter
AU - Leeming, Diana Julie
AU - Karsdal, Morten Asser
PY - 2012
Y1 - 2012
N2 - Ankylosing spondylitis (AS) is a chronic inflammation of the spine and the sacroiliac joints. Current markers of inflammation, such as C-reactive protein (CRP), are reflecting the production of an acute phase reactant rather than tissue specific inflammation, but the use of CRP as a diagnostic and prognostic marker for AS has not provided the sought accuracy and specificity. We hypothesized that local enzymatic activity in the disease-affected tissue, which is associated with extensive tissue turnover may, by cleavage, modify the CRP produced in the liver. These cleavage products may provide additional information on systemic inflammation as compared to that of full-length CRP. We investigated whether these CRP degradation products would provide additional diagnostic value in AS patients compared to full-length CRP.
AB - Ankylosing spondylitis (AS) is a chronic inflammation of the spine and the sacroiliac joints. Current markers of inflammation, such as C-reactive protein (CRP), are reflecting the production of an acute phase reactant rather than tissue specific inflammation, but the use of CRP as a diagnostic and prognostic marker for AS has not provided the sought accuracy and specificity. We hypothesized that local enzymatic activity in the disease-affected tissue, which is associated with extensive tissue turnover may, by cleavage, modify the CRP produced in the liver. These cleavage products may provide additional information on systemic inflammation as compared to that of full-length CRP. We investigated whether these CRP degradation products would provide additional diagnostic value in AS patients compared to full-length CRP.
M3 - Journal article
C2 - 22339813
SN - 0392-856X
VL - 30
SP - 371
EP - 379
JO - Clinical and Experimental Rheumatology
JF - Clinical and Experimental Rheumatology
IS - 3
ER -